With analysts around the globe predicting incredible growth in the 3D
printing sector in the coming years, Rainbow Coral Corp. (OTCBB: RBCC)
announced today that it will extend its investment position in Nano3D
Biosciences (n3D), a company on the cutting edge of the 3D bioprinting
RBCC took an equity interest in n3D in 2012, not long after the
companies formed a joint venture to market and develop new technologies
for the fast-growing, global biotechnology marketplace. The result of
their work has been the BiO Assay, the first commercially available 3D
bioprinting system designed for high throughput and high-content drug
screening. The automated toxicity assay uses biocompatible magnetic
nanoparticles to print cells into 3D structures much faster and more
affordably than competing bioprinting technologies.
Because the BiO Assay represents a revolution in pharmaceutical
research, offering better and faster results than have previously been
possible, RBCC is doubling down on its investment as new and exciting
forecasts for the future of the industry come in. In January, for
example, Visiongain predicted that the 3D printing market for healthcare
will generate more than $4 billion by 2018.
"Nano3D have been excellent partners in our efforts to capitalize on the
tremendous growth in demand for these bioprinting innovations," said
RBCC CEO Kimberly Palmer. "Interest is very high in this technology
because 3D bioprinting allows for an exceptional degree of
personalization and customization, and there's nothing that requires
more personalization than living human tissues."
RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and
develop new medical and research technology innovations to compete
alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott
Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow
Biosciences acquired an equity interest in n3D.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships
with biotechnology developers to deliver profitable new medical
technologies and innovations. For more information on our
growth-oriented business initiatives, please visit www.RainbowBioSciences.com.
For investment information and performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the Company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
[ Back To NFVZone's Homepage ]